NCT07490119

Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer

Efficacy and Safety of Becotatug Vedotin Combined With Cetuximab in the Later-line Treatment of Metastatic RAS Wild-type Colorectal Cancer: A Single-arm, Open-label, Single-center Phase II Clinical Study

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 31 (estimated)
• Sponsor: Fudan University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a single-arm, single-center, exploratory study aimed at exploring the treatment of RAS wild-type recurrent/metastatic colorectal cancer with the combination of becotatug vedotin and cetuximab as a salvage therapy

Conditions

• RAS Wild Type mCRC

Interventions

Type	Name	Description
DRUG	Becotatug Vedotin	On the first day of every 3 weeks, Becotatug Vedotin will be administered via intravenous infusion at 2.0 mg/kg.
DRUG	Cetuximab	On the first day of every 2 weeks, Cetuximab will be administered via intravenous infusion at 500mg/m2

Timeline

• Start date: 2026-06-01
• Primary completion: 2028-06-01
• Completion: 2029-06-01
• First posted: 2026-03-24
• Last updated: 2026-03-24